On November 15, Foresee Pharmaceuticals announced that the Phase III clinical trial (The Casppian Study) of its novel formulation drug FP-001 (CAMCEVI) for treating central precocious puberty (CPP) in children has received a second positive recommendation from the Data and Safety Monitoring Board (DSMB). The trial will proceed as planned without adjustments, marking another significant step toward bringing this new treatment to market.
Read more
